A rational approach to dose reduction of CDK4/6 inhibitors in the treatment of patients with advanced breast cancer: A narrative Review
The use of CDK4/6 inhibitors in the treatment of HR+/HER2– breast cancer (BC) has become increasingly widespread in recent years. When assessing the safety of CDK4/6 inhibitors, it was found that during therapy, a significant number of patients require a reduction in the initial dose of the drug due...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Russo |
| Izdano: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2025-07-01
|
| Serija: | Фармация и фармакология (Пятигорск) |
| Teme: | |
| Online pristup: | https://www.pharmpharm.ru/jour/article/view/1673 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|